A class of peptide-based drugs that mimic a gut hormone called glucagon-like peptide-1 has become one of the most talked-about developments in obesity medicine in decades. These compounds, known as GLP-1 receptor agonists, work by activating receptors that regulate appetite, insulin release, and blood sugar. Clinical trials have shown that they can produce substantial weight loss and, in patients who already have cardiovascular disease, reduce the risk of major cardiac events.
Yet a 2026 narrative review published in Therapeutic Advances in Endocrinology and Metabolism raises a pointed question: who actually gets access to these therapies? The review, authored by Ahmed Mohamed Mustafa and colleagues, argues that despite impressive clinical results, structural barriers are preventing GLP-1 receptor agonists from reaching many of the people who could benefit most. Without deliberate policy changes, the authors warn, the result could be a two-tiered treatment landscape where access reflects financial advantage rather than medical need.
What GLP-1 receptor agonists do
GLP-1 is a hormone released naturally by the gut after eating. It signals the pancreas to release insulin, slows how quickly the stomach empties, and communicates with the brain's appetite centers to reduce hunger. GLP-1 receptor agonists are synthetic peptides engineered to bind the same receptors and amplify these effects.
The review highlights that one member of this class, semaglutide, has demonstrated cardiovascular benefits in patients with pre-existing heart disease, not just weight reduction. That finding elevated the clinical profile of this drug class beyond metabolic management alone. For researchers and clinicians, it shifted the conversation from cosmetic outcomes to cardioprotective ones, making equitable access a more urgent issue.
Barriers inside primary care
Most people with obesity are managed in primary care settings, not specialist clinics. The review identifies several reasons why primary care providers struggle to integrate GLP-1 receptor agonists into routine practice.
First, there are training gaps. Many primary care physicians have not received formal education on obesity as a chronic disease, or on the pharmacological tools now available to treat it. This contributes to what researchers call clinical inertia, a tendency to delay or avoid initiating treatment even when clinical indicators suggest it would be appropriate.
Second, weight bias persists in clinical settings. Studies have documented that providers sometimes attribute obesity to personal choices rather than biological mechanisms, which can reduce the likelihood of prescribing effective interventions. The review frames this as a structural problem, not simply a matter of individual attitudes.
Together, these factors mean that even patients who have insurance coverage and see a primary care provider regularly may still not be offered these therapies.
Cost and coverage fragmentation
The review dedicates considerable attention to the financial barriers surrounding GLP-1 receptor agonists. These peptides carry high list prices, and insurance coverage is inconsistent. Publicly insured patients, including many enrolled in Medicaid, face particularly patchy access because coverage decisions vary by state and formulary.
The authors note that racial and ethnic minority groups, low-income communities, and publicly insured patients are less likely to receive prescriptions for these drugs and less likely to fill them when prescribed. This is especially significant because obesity-related diseases, including type 2 diabetes and cardiovascular disease, are disproportionately common in exactly these populations.
The practical result is a mismatch: the groups carrying the heaviest burden of metabolic disease are among the least likely to access the treatments that trials show can address it. The review describes this as a risk of entrenching a two-tiered system, where wealthier and better-insured patients benefit while others are left behind.
Real-world adherence
Even among patients who do receive prescriptions, real-world adherence data tell a more complicated story than clinical trial results. Trials typically enroll motivated participants with close monitoring and support. In everyday clinical practice, patients face supply shortages, side effect management without specialist guidance, and the challenge of long-term commitment to an injectable medication.
The review examines adherence patterns and finds that without structured, ongoing support, many patients discontinue treatment. Because these drugs appear to require continuous use to maintain their effects, discontinuation can lead to weight regain. This underscores that prescribing alone is insufficient. The research literature suggests that long-term treatment support structures are necessary for sustained outcomes.
Policy pathways the review identifies
The authors outline several areas where coordinated action could improve equitable access. These include reforming coverage and pricing policies to reduce out-of-pocket costs, particularly for publicly insured populations. They also point to workforce development as a priority, arguing that primary care providers need better training in obesity medicine to overcome clinical inertia and weight bias.
Person-centered care models, which tailor treatment plans to individual circumstances rather than applying a uniform protocol, are also highlighted as important. The review suggests that long-term treatment support, such as follow-up structures that help patients manage side effects and stay on therapy, is a necessary complement to prescribing.
None of these changes can happen in isolation, the authors argue. The word they use is aligned: reforms in coverage, training, clinical culture, and support systems need to move together to avoid incremental progress in one area being undermined by stagnation in another.
What the research means for the field
This review does not present new clinical trial data. Its contribution is in synthesizing existing evidence across prescribing patterns, adherence, health disparities, and policy to draw a broader picture of where the field stands. The authors make clear that the pharmacological promise of GLP-1 receptor agonists is real, but that clinical efficacy and population-level benefit are not the same thing.
For researchers studying metabolic peptides, the review highlights how access, not just mechanism or efficacy, shapes outcomes at the population level. A therapy that works in a trial but is unavailable to the patients who need it most represents an incomplete scientific success. The literature increasingly treats equitable implementation as part of the research agenda, not merely an afterthought to drug development.
Early data from real-world settings reinforce the gap between trial conditions and clinical practice. Researchers studying GLP-1 receptor agonists and related peptide classes will need to engage with these structural questions if the goal is translating laboratory and clinical findings into broad public health benefit.
